Treatment of aromatase (CYP19A1) inhibitor reduces fertility in porcine sperm

被引:5
|
作者
Oh, Jong-Nam [1 ]
Hwang, Jae Yeon [1 ]
Choi, Kwang-Hwan [1 ]
Lee, Chang-Kyu [1 ,2 ]
机构
[1] Seoul Natl Univ, Res Inst Agr & Life Sci, Dept Agr Biotechnol, Anim Biotechnol Major, Seoul 151921, South Korea
[2] Seoul Natl Univ, Inst Green Bio Sci & Technol, Designed Anim & Transplantat Res Inst, Kangwon Do 232916, South Korea
基金
新加坡国家研究基金会;
关键词
CYP19A1; protein; Fertility; Pig; Sperm; EARLY EMBRYO DEVELOPMENT; IN-VITRO FERTILIZATION; MESSENGER-RNA; CYTOCHROME-P450; AROMATASE; MALE REPRODUCTION; SEMINAL PLASMA; INFERTILE MEN; SWIM-UP; SPERMATOZOA; PERCOLL;
D O I
10.1017/S0967199414000781
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To ascertain whether aromatase (CYP19A1) expression is linked to sperm fertility of pigs, the present study determined the expression of the CYP19A1 gene in porcine sperm and its relationship with fertilization in vitro. First, to investigate its role in fertility, the presence of CYP19A1 of mRNA and protein expression in porcine sperm were confirmed by real-time (RT) or quantitative polymerase chain reaction (q-PCR) and by western blots. The expression levels were determined quantitatively using two sperm groups recovered by a Percoll gradient, which revealed that the sperm group with a low density had a higher penetration rate than that of the high-density group (P < 0.05). However, the expression level of CYP19A1 was not significantly different between the two groups. Secondly, to examine the effect of aromatase activity on fertilization, fresh semen was treated with a steroidal inhibitor, exemestane (50 M for 0.5 h), followed by the dose- and time-dependent viability test. Our results clearly showed that an exemestane treatment effect (P < 0.05) was found for both the sperm-penetration rate and the oocyte cleavage rate. These results indicated that CYP19A1 could be involved in sperm fertility and its expression in sperm plays an important role in fertilization.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 50 条
  • [31] Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
    Artigalas, Osvaldo
    Vanni, Tazio
    Hutz, Mara Helena
    Ashton-Prolla, Patricia
    Schwartz, Ida Vanessa
    BMC MEDICINE, 2015, 13
  • [32] Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study
    Conte, Benedetta
    Molinelli, Chiara
    Bisagni, Giancarlo
    Durando, Antonio
    Sanna, Giovanni
    Gori, Stefania
    Garrone, Ornella
    Tamberi, Stefano
    De Placido, Sabino
    Schettini, Francesco
    Pazzola, Antonio
    Ponzone, Riccardo
    Montemurro, Filippo
    Lunardi, Gianluigi
    Notaro, Rosario
    Turletti, Anna
    Bighin, Claudia
    Poggio, Francesca
    Buzzatti, Giulia
    Lambertini, Matteo
    Boni, Luca
    Del Mastro, Lucia
    CANCER RESEARCH, 2022, 82 (04)
  • [33] Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients
    Arnedos, M.
    Ferraldeschi, R.
    A'Hern, R.
    Hadfield, K.
    Roberts, S.
    Drury, S.
    Howell, A.
    Evans, D. G.
    Wardley, A. M.
    Smith, I. E.
    Newman, W. G.
    Dowsett, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] CYP19A1 Gene Polymorphism of Aromatase is Associated with Arterial Stiffness in Healthy Japanese People
    Hayashi, Koichiro
    Iemitsu, Motoyuki
    Murakami, Haruka
    Sanada, Kiyoshi
    Kawano, Hiroshi
    Gando, Yuko
    Tanaka, Noriko
    Kawakami, Ryoko
    Miyachi, Motohiko
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2017, 49 (05): : 86 - 86
  • [35] Mechanisms in the regulation of aromatase/CYP19A1 gene expression during human trophoblast differentiation
    Mendelson, Carole R.
    Kumar, Premlata
    ENDOCRINE JOURNAL, 2010, 57 : S257 - S257
  • [36] Hypogonadism Associated with Cyp19a1 (Aromatase) Posttranscriptional Upregulation in Celf1 Knockout Mice
    Boulanger, Gaella
    Cibois, Marie
    Viet, Justine
    Fostier, Alexis
    Deschamps, Stephane
    Pastezeur, Sylvain
    Massart, Catherine
    Gschloessl, Bernhard
    Gautier-Courteille, Carole
    Paillard, Luc
    MOLECULAR AND CELLULAR BIOLOGY, 2015, 35 (18) : 3244 - 3253
  • [37] The Aromatase Gene (CYP19A1) Variants and Circulating Hepatocyte Growth Factor in Postmenopausal Women
    Lin, Jennifer H.
    Gunter, Marc J.
    Manson, Joann E.
    Rexrode, Kathryn M.
    Cook, Nancy R.
    Kraft, Peter
    Cochrane, Barbara B.
    Chlebowski, Rowan T.
    Ho, Gloria Y. F.
    Zhang, Shumin M.
    PLOS ONE, 2012, 7 (07):
  • [38] Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.
    Mao, J.
    Su, I.
    Feng, R.
    Desai, K.
    Horn, M.
    Chan, D.
    DeMichele, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy
    Mazzuca, Federica
    Botticelli, Andrea
    Mazzotti, Eva
    La Torre, Marco
    Borro, Marina
    Marchetti, Luca
    Maddalena, Chiara
    Gentile, Giovanna
    Simmaco, Maurizio
    Marchetti, Paolo
    EURASIAN JOURNAL OF MEDICINE, 2016, 48 (01): : 10 - 14
  • [40] Correction: Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
    Luca Magnani
    Gianmaria Frigè
    Raffaella Maria Gadaleta
    Giacomo Corleone
    Sonia Fabris
    Mannus H Kempe
    Pernette J Vershure
    Iros Barozzi
    Valentina Vircillo
    Sung-Pil Hong
    Ylenia Perone
    Massimo Saini
    Andreas Trumpp
    Giuseppe Viale
    Antonino Neri
    Simak Ali
    Marco Angelo Colleoni
    Giancarlo Pruneri
    Saverio Minucci
    Nature Genetics, 2017, 49 : 970 - 970